ArticleBalkan medical journal2022
Hemophagocytic Lymphohistiocytosis
Article in Balkan medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study.Frontiers in immunology · 2024Trial
- Nanomaterials Drive In Vivo CAR Immune Cells Engineering.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Article
- Hemophagocytic Lymphohistiocytosis Triggered byClinical case reports · 2026Article
- Novel perspectives on the rare hemophagocytic lymphohistiocytosis: insights from a multi-center retrospective cohort.Frontiers in medicine · 2026Article
- Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report.Frontiers in immunology · 2026Article
- Hemophagocytic Lymphohistiocytosis-like syndrome following rotavirus infection in a pediatric patient with severe pneumonia: a case report and literature review.Italian journal of pediatrics · 2025Review
- Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis.Infection · 2025Article
- Article
- Article
- Simultaneous intravascular large B‑cell lymphoma and papillary thyroid carcinoma: A case report.Molecular and clinical oncology · 2025Article
- Management Challenge of Coexistence of Macrophage Activation Syndrome, Systemic Lupus Erythematosus, and Hepatitis B: Case Report.Clinical case reports · 2025Article
- Predicting 30-day mortality in hemophagocytic lymphohistiocytosis: clinical features, biochemical parameters, and machine learning insights.Annals of hematology · 2025Article
- Plasma proteomics in pediatric patients with sepsis- hopes and challenges.Clinical proteomics · 2025Review
- Extranodal natural killer/T-cell lymphoma with secondary haemophagocytic lymphohistiocytosis simulating orbital inflammatory disease.BMJ case reports · 2025Article
- Brucellosis-associated hemophagocytic lymphohistiocytosis: a case report and literature review.Frontiers in medicine · 2025Article
- Clinical spectrum of primary hemophagocytic lymphohistiocytosis: experience of reference centers in Central and Southeast Anatolia.Annals of hematology · 2025Article
- Prognostic value of blood inflammatory composite markers in the survival of pediatric patients with secondary hemophagocytic lymphohistiocytosis.Frontiers in pediatrics · 2025Article
- Brucella-associated hemophagocytic syndrome: case report of a potentially life-threatening condition and literature review.Frontiers in immunology · 2025Review
- Secondary Hemophagocytic Lymphohistiocytosis Triggered by Subdural Empyema due to Streptococcus constellatus: A Rare Triad.Journal of Brown hospital medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is an aggressive life-threatening disease that consists of uncontrolled activated lymphocytes and macrophages that secrete excessive cytokines. Symptoms and laboratory findings of HLH include prolonged fever, cytopenia, hepatosplenomegaly, liver dysfunction, hypertriglyceridemia, hyperferritinemia, increased soluble interleukin-2 receptor, low fibrinogen, and neurological problems. HLH has two forms: primary (familial autosomal recessive) or secondary (related to infections, malignancy, autoimmune and metabolic disorders, transplantations, chimeric antigen receptor T-cell therapies, etc.) form. As underlying conditions in HLH varied, clinical findings are nonspecific and disease diagnosis is challenging. Furthermore, patients diagnosed with primary HLH can have a secondary triggering agent, such as infection. Thus, there is no clear-cut distinction between these two forms. Abnormal immune response and a low number or absence of natural killer cells and cytotoxic T-lymphocytes are hallmarks of HLH. Despite the early and aggressive treatment, HLH is a deadly disease. Urgent immunosuppressive therapy is necessary to control hyperinflammation. Hematopoietic stem cell transplantation is a curative treatment in familial forms. Targeted therapy with emapalumab was also recently reported to be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.